CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenues	$ 95	$ 194	$ 285	$ 584
Cost of revenues	(3)	(6)	(9)	(18)
Gross profit	92	188	276	566
Research and development expenses	(6,885)	(4,965)	(18,489)	(12,859)
Less participation by the Office of the Chief Scientist and other parties	37	3	3,411	1,546
Research and development expenses, net	(6,848)	(4,962)	(15,078)	(11,313)
General and administrative expenses	(2,531)	(1,159)	(6,335)	(4,260)
Operating loss	(9,287)	(5,933)	(21,137)	(15,007)
Financial income, net	11	253	401	842
Net loss for the period	$ (9,276)	$ (5,680)	$ (20,736)	$ (14,165)
Loss per share:
Basic and diluted net loss per share	$ (0.14)	$ (0.10)	$ (0.33)	$ (0.26)
Weighted average number of shares used in computing basic and diluted net loss per share	65,607,976	58,358,476	62,098,498	54,507,538